Plasma or serum 5-hydroxyindoleacetic acid can be used interchangeably in patients with neuroendocrine tumours.

MLA

Ewang-Emukowhate, Mfon, et al. “Plasma or Serum 5-Hydroxyindoleacetic Acid Can Be Used Interchangeably in Patients with Neuroendocrine Tumours.” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 83, no. 8, Dec. 2023, pp. 576–81. EBSCOhost, https://doi.org/10.1080/00365513.2023.2286645.

APA

Ewang-Emukowhate, M., Subramaniam, K., Lam, F., Hayes, A., Mandair, D., Toumpanakis, C., Grossman, A., Nair, D., & Caplin, M. (2023). Plasma or serum 5-hydroxyindoleacetic acid can be used interchangeably in patients with neuroendocrine tumours. Scandinavian Journal of Clinical and Laboratory Investigation, 83(8), 576–581. https://doi.org/10.1080/00365513.2023.2286645

Chicago

Ewang-Emukowhate, Mfon, Krithika Subramaniam, Francis Lam, Aimee Hayes, Dalvinder Mandair, Christos Toumpanakis, Ashley Grossman, Devaki Nair, and Martyn Caplin. 2023. “Plasma or Serum 5-Hydroxyindoleacetic Acid Can Be Used Interchangeably in Patients with Neuroendocrine Tumours.” Scandinavian Journal of Clinical and Laboratory Investigation 83 (8): 576–81. doi:10.1080/00365513.2023.2286645.